Medisse is pleased to announced that its shareholders have appointed Alexander Vos to its Supervisory Board. Mr. Vos is currently CEO of Pharmacell , a company that provides contract services in the area of human cell and tissue culturing. Mr. Vos is a seasoned executive with more than 20 years of leadership experience in the pharmaceutical and biotech industries. He previously held senior management positions at Genzyme Europe, MediService (Switzerland) and PAION (Germany).
"Alexander Vos 's broad experience will be of great value to Medisse as it expands its development capabilities. We will be able to build on his in-depth knowledge of the drug and medical device development processes to bring Medisse's lead product for anti adhesion to market," said Will Hazenberg , Chairman of the Supervisory Board.
"Today's solutions for resorbable implants in general, and anti adhesion in particular are still suboptimal. I believe that Medisse's resorbable flexible implant technology could potentially fill these huge unmet medical needs," said Alexander Vos . "I look forward to supporting the Medisse leadership team in progressing this innovative technology to the stage of commercialization." Medisse is pleased to announced that its shareholders have appointed Alexander Vos to its Supervisory Board. Mr. Vos is currently CEO of Pharmacell , a company that provides contract services in the area of human cell and tissue culturing. Mr. Vos is a seasoned executive with more than 20 years of leadership experience in the pharmaceutical and biotech industries. He previously held senior management positions at Genzyme Europe, MediService (Switzerland) and PAION (Germany).
"Alexander Vos 's broad experience will be of great value to Medisse as it expands its development capabilities. We will be able to build on his in-depth knowledge of the drug and medical device development processes to bring Medisse's lead product for anti adhesion to market," said Will Hazenberg , Chairman of the Supervisory Board.
"Today's solutions for resorbable implants in general, and anti adhesion in particular are still suboptimal. I believe that Medisse's resorbable flexible implant technology could potentially fill these huge unmet medical needs," said Alexander Vos . "I look forward to supporting the Medisse leadership team in progressing this innovative technology to the stage of commercialization."
Prior to joining PharmaCell, Mr. Vos was COO at PAION AG (Frankfurt : PA8). From 2000 to 2004, Mr. Vos was CEO of MediService AG (Switzerland), one of the leading specialty pharmacy service companies in Europe, which was successfully sold to Galenica AG. From 1995 until 2000, Mr Vos held several executive positions at Genzyme Europe. Mr. Vos started his career as a strategy consultant at McKinsey & Co. Mr. Vos pursued graduate studies of pharmacy and pharmacology in Amsterdam, the Netherlands, and at the Mayo Clinic in the U.S., and holds an MBA from Stanford Graduate School of Business.